Central Composite Designed Ezetimibe Solid Dispersion for Dissolution Enhancement: Synthesis and In Vitro Evaluation

Abstract

Aim: The current research is focused on increasing aqueous solubility and dissolution of BCS class II drug by using modified solvent evaporation technique to produce solid dispersions of ezetimibe (EZSD) using gelucire 50/13 and polyvinyl pyrollidone K30. Methodology & results: Central composite design analyzed the effect of gelucire 50/13 and polyvinyl pyrollidone K30 on the percentage of drug released in 5 and 30 min. Ezetimibe (EZ) aqueous saturation solubility (4.56 ± 0.94 μg/ml) was increased 25-fold in EZSD (115 ± 3.41 μg/ml). Cumulative drug release from EZ and optimized EZSD were observed 24.67 and 87.54% within 1 h, respectively. Conclusion: Manufacturing EZSD using modified solvent evaporation technique using rotary evaporator holds great promise for enhancing EZ's solubility and dissolution.

Graphical abstract

Keywords:

• ezetimibe
• gelucire 50/13
• polyvinyl pyrollidone K30
• rotary evaporator
• solvent evaporation technique

View correction statement:

Corrigendum

Author contributions

N Sharma: Formulation development and optimization. S Singh: Physicochemical characterization, in vitro evaluation and stability study.

Acknowledgments

The authors would like to thank Chitkara College of Pharmacy, Chitkara University, Punjab, India for supporting and encouraging this research work. The authors would like to acknowledge Stat-Ease, Inc for Design-Expert software (trial version 11.1.2.0, Stat-Ease Inc., MN). The authors would also like to acknowledge CambridgeSoft for ChemDraw Ultra 12.0.2.1076 and Advanced Chemistry Development, Inc for ACD/ChemSketch (Freeware 2017.2.1).

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.